AnaptysBio enters new strategic alliances for antibody discovery AnaptysBio, Inc., a privately-held therapeutic antibody business, today announced the initiation of fresh strategic alliances with two companions: Novartis and an undisclosed second pharmaceutical firm www.erectafil.org http://erectafil.org . Related StoriesNew Histone Antibody Specificity Data source allows scientists to find right antibodies for biomedical researchAridis expands, accelerates current AR-301 Phase 2a research for treatment of severe pneumonia in the U.S.Calcitonin-gene related peptide antibody inhibition shows migraine prevention promiseAnaptysBio’s proprietary SHM-XEL platform, which couples fully human antibody libraries with in vitro somatic hypermutation in mammalian cells to create high affinity lead candidates, replicates key features of the human being disease fighting capability and overcomes limitations of prior antibody technologies.
New analysis from Frost & Sullivan reveals that the European basic safety syringes market generated a market revenue of USD 13 million in 2003 and can be projected to dual by 2010. Considering that needlestick injuries total a staggering one million in Europe every year, and that 16 to 25 percent of these are from the using single-use syringes, the market for safety syringes – which prevent needlestick injuries along with discourage reuse – looks extremely promising. ‘A legislation that’s sympathetic to the problems faced by the number of needlestick accidents occurring in European countries and the hazards of disease by over 20 pathogens that health workers encounter is needed,’ comments Frost & Sullivan Analysis Analyst Kavitha Ravikumar.